Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
暂无分享，去创建一个
R. Gelber | L. Pusztai | J. Baselga | H. Gómez | A. Goldhirsch | S. Cosimo | M. Untch | M. Piccart-Gebhart | V. Semiglazov | Tsai-Wang Chang | H. Eidtmann | I. Bradbury | K. Fauria | Z. Horváth | M. Pálácova | C. Aura | J. Sohn | G. Aktan | V. Probachai | G. Lerzo | P. Dinh | E. Azambuja | V. V. Dooren | J. Dômont | G. Kunz | L. Tseng | M. Coccia-Portugal | V. Dooren